Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 141
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT05265273 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Ge… |
Nipocalimab | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | Janssen Research & Development, L… | United States, Japan, Netherlands, Poland · C.S. Mott… | 2022-07-20 → 2029-07-02 | Ouvrir |
| NCT06055959 ziMyG — A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Partic… |
Zilucoplan | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, Italy, Poland, South Korea, United Kin… | 2024-10-16 → 2026-12-25 | Ouvrir |
| NCT07596901 Study of Aritinercept in Patients With Generalized Myasthenia Gravis |
Aritinercept | Myasthénie | Phase 1/2 | RECRUITING | En attente / non publié | Aurinia Pharmaceuticals Inc. | United States · Aurinia Investigational Site, Altamon… | 2026-04-22 → 2029-03-02 | Ouvrir |
| NCT06447597 A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gra… |
B007 | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | Shanghai Jiaolian Drug Research a… | China · Affiliated Hospital of Zunyi Medical College,… | 2024-07-01 → 2026-12-30 | Ouvrir |
| NCT06540144 An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizuma… |
rozanolixizumab | Myasthénie | Phase 3 | ENROLLING_BY_INVITATION | En attente / non publié | UCB Biopharma SRL | Italy, Japan, Poland, Taiwan, Turkey (Türkiye) · Mg00… | 2024-10-08 → 2027-08-17 | Ouvrir |
| NCT06359041 RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Pa… |
CABA-201 | Myasthénie | Phase 1/2 | RECRUITING | En attente / non publié | Cabaletta Bio | United States · Baylor College of Medicine Neurology … | 2024-12-17 → 2029-09 | Ouvrir |
| NCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Descartes-08 | Myasthénie | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Cartesian Therapeutics | United States, Canada · Allegheny Health Network, Pit… | 2019-12-04 → 2026-09-30 | Ouvrir |
| NCT07571525 TAILOR-MG — Thymic Disease, Autoimmunity, and Neuromuscular Junction In… |
TAILOR-MG — Thymic Disease, Autoi… | Myasthénie | À vérifier | NOT_YET_RECRUITING | En attente / non publié | IRCCS San Raffaele | Italy · IRCCS Ospedale San Raffaele, Milan, Italy | 2026-09-15 → 2029-12-01 | Ouvrir |
| NCT07337785 CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Dis… |
CD19/BCMA-targeted CAR-T cells | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | Tongji Hospital | China · Tongji Hospital, Tongji Medical College, Huaz… | 2025-12-12 → 2028-11-01 | Ouvrir |
| NCT04524273 MINT — Myasthenia Gravis Inebilizumab Trial |
Inebilizumab | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Amgen | United States, Argentina, Belarus, Brazil, Canada, Ch… | 2020-10-15 → 2029-06-07 | Ouvrir |
| NCT07593911 ArchAid-002 — A Study to Evaluate MTM-H-001 Injection in Adult Patients… |
MTM-H-001 Injection | Myasthénie | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Beijing GoBroad Hospital | China · Beijing GoBroad Hospital, Beijing, China | 2026-06 → 2031-06 | Ouvrir |
| NCT00704626 SAA — Serum Auto-Antibodies in Neurological Diseases |
SAA — Serum Auto-Antibodies in Ne… | Myasthénie | À vérifier | ENROLLING_BY_INVITATION | En attente / non publié | University of California, Davis | United States · University of California, Davis, Sacr… | 2002-01 → 2031-03 | Ouvrir |
| NCT07595653 POEMA — A Study to Evaluate the Impact of Efgartigimod on Overall Disea… |
POEMA — A Study to Evaluate the I… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | argenx | Italy · A.O.U. Careggi, Florence, Italy | A.O.U. Cons… | 2026-02-25 → 2028-07 | Ouvrir |
| NCT07246564 Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adul… |
rozanolixizumab | Myasthénie | Phase 4 | RECRUITING | En attente / non publié | UCB Biopharma SRL | China · Mg0033 20040, Beijing, China | Mg0033 20172, … | 2025-12-01 → 2027-10-15 | Ouvrir |
| NCT04980495 ADAPT NXT — An Open-label Study to Investigate the Clinical Efficacy of… |
Efgartigimod IV | Myasthénie | Phase 3 | COMPLETED | En attente / non publié | argenx | United States, Austria, Belgium, Canada, France, Geor… | 2021-12-16 → 2025-10-06 | Ouvrir |
| NCT06958939 The Safety and Efficacy of S103 in the Treatment of Refractory Generali… |
Dose level 1 group | Myasthénie | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Ting Chang, MD | China · The Second Affiliated Hospital of Air Force M… | 2025-05-01 → 2028-04-30 | Ouvrir |
| NCT07622342 A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Grav… |
SHR-2173 injection | Myasthénie | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Guangdong Hengrui Pharmaceutical … | China · Huashan Hospital, Fudan University, Shanghai,… | 2026-06 → 2027-12 | Ouvrir |
| NCT06700616 MG Cohort — A Study in Patients With Myasthenia Gravis in China |
MG Cohort — A Study in Patients W… | Myasthénie | À vérifier | ACTIVE_NOT_RECRUITING | En attente / non publié | AstraZeneca | China · Research Site, Beijing, China | Research Site… | 2024-09-26 → 2027-12-30 | Ouvrir |
| NCT06002945 EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Grav… |
EXPLORE-MG2 — Exploring Outcomes … | Myasthénie | À vérifier | COMPLETED | En attente / non publié | Yale University | United States · Cedars Sinai Medical Center, Los Ange… | 2021-01-12 → 2025-05-31 | Ouvrir |
| NCT07570589 REAL MG PRO — Monitor the Evolution of Myasthenia Gravis Symptoms in Re… |
REAL MG PRO — Monitor the Evoluti… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | Centre Hospitalier Universitaire … | France · Ch de Boulogne sur Mer, Boulogne-sur-Mer, Fr… | 2026-06-15 → 2028-03 | Ouvrir |
| NCT07649187 Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG |
Depressive Tendency and Counselin… | Myasthénie | Non applicable | COMPLETED | En attente / non publié | Ming-Hsing Chang | Taiwan · Shin Kong Wu Ho-Su Memorial Hospital, Taipei… | 2024-01-01 → 2025-12-31 | Ouvrir |
| NCT06866652 MyaRESP — Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I … |
MyaRESP — Evaluating Dyspnea in A… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | Institut de Myologie, France | France · Institute of Myology, Paris, France | 2026-04-08 → 2028-06 | Ouvrir |
| NCT05556096 Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia G… |
ALXN1720 | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Alexion Pharmaceuticals, Inc. | United States, Argentina, Austria, Brazil, Canada, Ch… | 2022-11-21 → 2027-08-31 | Ouvrir |
| NCT06909253 MG-ARCADIA — Ravulizumab Treatment Outcomes in Patients With Generalize… |
Ravulizumab | Myasthénie | À vérifier | RECRUITING | En attente / non publié | AstraZeneca | Poland · Research Site, Bydgoszcz, Poland | Research … | 2025-05-15 → 2029-12-31 | Ouvrir |
| NCT03490539 PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis |
Mycophenolate Mofetil | Myasthénie | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Canada · Beth Israel Deaconess Medical… | 2018-05-07 → 2021-01-31 | Ouvrir |